3rd Quarter - Report

DOTCHIN & ASSOCIATES, LLC for EMERGENT BIOSOLUTIONS

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

NDAA for Fiscal Year 2022- provisions related to biological and chemical defense and access to naloxone

LobbyistCovered position, as disclosed
ROBERT J. DOTCHIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

S.4231 - Preparing for the Next Pandemic Act

LobbyistCovered position, as disclosed
ROBERT J. DOTCHIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 4231 (117th)

Budget/Appropriations BUD

State Opioid Response Grants funding Substance Abuse and Mental Health Block Grant funding H.R. 2379 The State Opioid Response Grant Authorization Act of 2021 Appropriations funding for Fiscal Year 2022

LobbyistCovered position, as disclosed
ROBERT J. DOTCHIN —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 2379 (117th)

Alcohol and Drug Abuse ALC

CARA 3.0 - Comprehensive Addiction and Recovery Act Opioid and heroin addiction legislation, naloxone access and awareness and opioid prescribing guidelines H.R 2366 S.1457 - Stop Fentanyl Act H.R. 5224 - Preventing Overdoses and Saving Lives Act of 2021 Issues related to the development, manufacture, and distribution of coronavirus vaccines.

LobbyistCovered position, as disclosed
ROBERT J. DOTCHIN —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 2366 (117th), H.R. 5224 (117th), S. 1457 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.